- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07318831
Faasi II -tutkimus Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide -yhdistelmästä vastustuskykyisessä/tilassa uusiutuneessa neuroblastoomassa lapsilla
Faasi II -tutkimus kidamidin yhdistämisestä dinutuksimab beetaan, irinotekaaniin ja temozolomiidiin refraktoriin tai uusiutuneen neuroblastoman hoidossa lapsilla
This is a Phase II clinical trial investigating the effectiveness and safety of a four-drug combination-Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide-for children with relapsed or refractory neuroblastoma. The primary goal is to evaluate how well this regimen works to control the cancer, while the secondary goal is to closely monitor its safety and side effects in these young patients.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Yan Jin
- Puhelinnumero: +8613212163398
- Sähköposti: myyaner520@163.com
Opiskelupaikat
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kiina, 300060
- Rekrytointi
- Tianjin Medical University Cancer Institute & Hospital
-
Ottaa yhteyttä:
- Yan Jin, PhD
- Puhelinnumero: 0086-23340123
- Sähköposti: jinyan0713@tmu.edu.cn
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age 0-18 years at enrolment.
- Histologically diagnosed neuroblastoma defined as high-risk according to the International Neuroblastoma Risk Group classification or Chinese consensus/guideline risk classification.
- Relapsed or refractory neuroblastoma. Relapse is defined as any recurrence of neuroblastoma. Refractory disease is defined as inadequate response to prior therapy, including partial response, minor response or stable disease, followed by progression.
- Prior exposure to histone deacetylase inhibitors, DNA methylation inhibitors or GD2 monoclonal antibodies does not preclude eligibility.
- Presence of evaluable disease.
- Performance status of Lansky score >=50%, Karnofsky score >=50% or ECOG performance status <=3.
- Life expectancy >=12 weeks.
- Adequate bone marrow function: for patients without bone marrow disease, platelet count >=75 x 10^9/L, absolute neutrophil count >=0.75 x 10^9/L and haemoglobin >=8 g/dL with transfusion permitted; for patients with bone marrow disease, platelet count >=50 x 10^9/L, absolute neutrophil count >=0.5 x 10^9/L and haemoglobin >=8 g/dL with transfusion permitted.
- Renal function without clinically significant proteinuria. If urine dipstick protein is >=2+, protein:creatinine ratio must be <0.5 or 24-hour protein excretion must be <0.5 g.
- Serum creatinine <=1.5 x upper limit of normal or calculated glomerular filtration rate >=60 mL/min/1.73 m2 if serum creatinine is higher.
- Adequate liver function: AST or ALT <=2.5 x upper limit of normal and total bilirubin <=1.5 x upper limit of normal; in the presence of hepatic metastases, AST or ALT <=5 x upper limit of normal and total bilirubin <=2.5 x upper limit of normal.
- Cardiac shortening fraction >=29% on echocardiography.
- Coagulation function with INR <=1.5 and APTT <=1.5 x upper limit of normal for age if not receiving anticoagulation; anticoagulation is permitted if INR or APTT is within the therapeutic range and the dose has been stable for at least 2 weeks before registration.
- Oxygen saturation >94% without supplemental oxygen. Ability to comply with the visit schedule and other protocol requirements.
Exclusion Criteria:
- Patients with CTCAE v5.0 Grade 3 or higher toxicities involving hearing impairment, hematologic disorders, hepatic, or renal diseases.
- Patients with CTCAE v5.0 Grade 2 or higher neurotoxicity.
- Major surgical procedure within 14 days prior to the first dose of the study drug.
- Severe infection (requiring IV antibiotics, antifungals, or antivirals) within one week prior to treatment, or unexplained fever >38.5°C during screening or before the first dose.
- Congenital or acquired immunodeficiency, or active infectious diseases such as HIV or active hepatitis (with transaminase levels not meeting inclusion criteria; HBV DNA ≥1000 IU/mL; HCV RNA ≥1000 IU/mL). Chronic HBV carriers with HBV DNA <2000 IU/mL may be enrolled if they receive concurrent antiviral therapy during the trial.
- Any concomitant condition that, in the investigator's judgment, seriously jeopardizes patient safety, may confound the study results, or could impede the patient's completion of the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Chidamide
|
Chidamide (C): 5 mg/10 kg (maximum single dose: 30 mg), administered twice per week. The medication follows a schedule of two weeks on treatment followed by one week off. Specifically, it is taken orally on Days 0, 3, 7, and 10 of each three-week cycle. Chidamide is initiated one day before the start of chemotherapy. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Objective Response Rate(ORR)
Aikaikkuna: Baseline and after Cycles 3, 5 or 6, 7 or 8, and 10 (each cycle is 21 days; up to 30 weeks), or earlier if clinically indicated, during treatment and follow-up (up to 5 years).
|
The primary endpoint is defined identically in both sources as the confirmed best overall response of CR or PR per the revised INRC during up to 10 cycles. |
Baseline and after Cycles 3, 5 or 6, 7 or 8, and 10 (each cycle is 21 days; up to 30 weeks), or earlier if clinically indicated, during treatment and follow-up (up to 5 years).
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Progression-Free Survival(PFS)
Aikaikkuna: From the date of the first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever occurs first, assessed up to 5 years.
|
From the date of the first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever occurs first, assessed up to 5 years.
|
|
|
Event-Free Survival(EFS)
Aikaikkuna: From the date of the first dose of study treatment until the first documented disease progression or relapse per the revised INRC, development of a secondary malignancy, or death from any cause, whichever occurs first, assessed up to 5 years.
|
From the date of the first dose of study treatment until the first documented disease progression or relapse per the revised INRC, development of a secondary malignancy, or death from any cause, whichever occurs first, assessed up to 5 years.
|
|
|
Duration of Response(DOR)
Aikaikkuna: From the date of first documented complete or partial response per the revised INRC until the date of first documented disease progression or date of death from any cause, whichever occurs first, assessed up to 5 years.
|
From the date of first documented complete or partial response per the revised INRC until the date of first documented disease progression or date of death from any cause, whichever occurs first, assessed up to 5 years.
|
|
|
Overall Survival (OS)
Aikaikkuna: From the date of the first dose of study treatment until the date of death from any cause, assessed up to 5 years.
|
From the date of the first dose of study treatment until the date of death from any cause, assessed up to 5 years.
|
|
|
Safety assession
Aikaikkuna: Safety will be assessed from the first dose through 28 days after the last dose or initiation of new anticancer therapy
|
Safety will be assessed from the first dose through 28 days after the last dose or initiation of new anticancer therapy, whichever occurs first, using adverse events, serious adverse events, grade, seriousness, relatedness, dose modifications and treatment discontinuation. |
Safety will be assessed from the first dose through 28 days after the last dose or initiation of new anticancer therapy
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Exploratory endpoints
Aikaikkuna: Baseline (after enrolment and before the first dose), during treatment (up to 2 years), and at relapse or disease progression.
|
Exploratory endpoints include changes in immune cells and cytokines; transcriptomic assessment of cell state and its association with efficacy and survival; immunohistochemistry, immunocytochemistry or flow cytometry assessment of GD2 expression; assessment of ST8SIA1 and YAP1 expression; exploration of NSE, VMA, LDH and ferritin as biomarkers of efficacy and survival; and monitoring of plasma ctDNA ST8SIA1 methylation before treatment, after treatment and at relapse or progression. |
Baseline (after enrolment and before the first dose), during treatment (up to 2 years), and at relapse or disease progression.
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat
- Neoplasmat histologisen tyypin mukaan
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Neoplasmat, neuroepiteliaaliset
- Neuroektodermaaliset kasvaimet
- Neoplasmat, sukusolut ja alkiot
- Kasvaimet, hermokudos
- Neuroektodermaaliset kasvaimet, primitiiviset, perifeeriset
- Neuroektodermaaliset kasvaimet, primitiiviset
- Neuroblastooma
- Orgaaniset kemikaalit
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Atsolit
- Camptothecin
- Alkaloidit
- Dacarbatsiini
- Triatseenit
- Imidatsolit
- Temotsolomidi
- Irinotekaani
- dinatutsimabi
Muut tutkimustunnusnumerot
- E20251314
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .